Ogasawara Yoji, Amexis Georgios, Yamaguchi Hiroki, Kajigaya Sachiko, Leppla Stephan H, Young Neal S
Hematology Branch, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
In Vivo. 2006 May-Jun;20(3):319-24.
Viral-like particles (VLPs) of parvovirus B19 were employed as an antigen carrier to present antigenic determinants of Bacillus anthracis. The small-loop peptide and the full-length domain 4 of protective antigen (PA) were chosen as immunogens for presentation on the VLP-capsid surface and subsequent immunization of BALB/c mice. The recombinant VLPs induced anti-PA IgG titers of up to 2.5 x 10(4). Neutralization assays showed that the recombinant VLPs elicited neutralizing anti-PA antibody titers of up to 1:400 and showed potential for the prevention of lethal toxin-induced mortality of mouse-macrophage cells (RAW264.7). In postimmune sera, no anti-PA titers were detected against synthetic small-loop peptide. Recombinant VLPs demonstrated the capacity to retain the immunogenicity of the displayed microbial PA-epitopes and elicited robust levels of anti-PA antibody titers. These findings suggest that the recombinant VLPs of parvovirus B19 have potential as an additional tool in the development of sub-unit vaccines.
细小病毒B19的病毒样颗粒（VLPs）被用作抗原载体来呈递炭疽芽孢杆菌的抗原决定簇。选择小环肽和保护性抗原（PA）的全长结构域4作为免疫原，用于在VLP衣壳表面呈递并随后免疫BALB/c小鼠。重组VLPs诱导的抗PA IgG滴度高达2.5×10⁴。中和试验表明，重组VLPs引发的中和抗PA抗体滴度高达1:400，并显示出预防致死毒素诱导的小鼠巨噬细胞（RAW264.7）死亡的潜力。在免疫后血清中，未检测到针对合成小环肽的抗PA滴度。重组VLPs证明有能力保留所展示的微生物PA表位的免疫原性，并引发高水平的抗PA抗体滴度。这些发现表明，细小病毒B19的重组VLPs有潜力作为亚单位疫苗开发中的一种额外工具。
